MORRISVILLE, N.C., March 31, 2020 – Six new abstracts & posters showcasing MyoStrain® were published as part of the American College of Cardiology’s (ACC) 69th Annual Scientific Session & Expo. The conference, which was scheduled to take place in Chicago, Illinois from March 28-30, was shifted to a virtual experience due to the COVID-19 pandemic.
Three of the published abstracts discussed MyoStrain’s utility in predicting, detecting and managing cardiotoxicity from cancer therapies based on data from the PREFECT study (NCT03543228).
Another abstract featured MyoStrain as a tool for chest pain triage in emergency rooms, utilizing hyperventilation as stressor agent to identify ischemia. The other abstracts highlighted MyoStrain’s utilization in patients with myocarditis and valvular disease.
These publications at ACC 2020 demonstrate MyoStrain’s continued progress towards becoming the standard of care for assisting physicians to measure cardiac health.
To view the presented MyoStrain abstracts and presentations, see the list below:
Wang T, et al. Prospective echocardiography and magnetic resonance imaging validation study of a geometric model for calculating left ventricular ejection fraction from strain in valvular heart disease. ACC 2020.
About Myocardial Solutions, Inc.
Myocardial Solutions, Inc. (MSI) is a medical technology company working to transform the cardiac and cancer care continuum. Leveraging more than 400 publications in clinical research and development, MSI’s proprietary technology, MyoStrain®, is a 10-minute, non-invasive heart function test providing physicians with sensitive diagnostic markers to support the early assessment and individualized treatment of heart dysfunction. MyoStrain has received FDA-510(k) pre-market clearance, CE-mark certification, and is commercially available in the United States and Europe.
To learn more about MyoStrain, visit myocardialsolutions.com or connect with us on LinkedIn and Twitter @myocardialsoln.